Treatment and Clinicopathological Characteristics of Lupus Nephritis with Anti-Neutrophil Cytoplasmic Antibody Positivity: a Case–control Study

Cui Li,Min-Lin Zhou,Dan-Dan Liang,Jing-Jing Wang,Jing Yang,Cai-Hong Zeng,Zhi-Hong Liu,Hai-Tao Zhang
DOI: https://doi.org/10.1136/bmjopen-2016-015668
IF: 3.006
2017-01-01
BMJ Open
Abstract:Objective To assess the clinical features, pathological presentations, treatments and outcomes of lupus nephritis (LN) with anti-neutrophil cytoplasmic antibody (ANCA) positivity. Design A case-control study. Methods Patients (n=49) were retrospectively included from Jinling Hospital in China if presenting with biopsyproven ANCA-positive LN between 1985 and 2008. Clinicopathological characteristics and outcomes were analysed and compared with those of a control group (n=1279). We further compared treatment responses and outcomes of ANCA-positive LN patients based on the treatment issued. Results The study included 40 women and 9 men (median age 33 years at biopsy): 38 with myeloperoxidase (MPO)-ANCA, 7 with proteinase 3 (PR3)-ANCA and 4 with double positivity. ANCA-positive LN patients exhibited higher haematuria, serum creatinine levels and systemic lupus erythematosus disease activity index scores. On pathological evaluation, class IV LN was predominant, accounting for 61.22% of cases. Light microscopy revealed significantly higher activity index and chronicity index scores, including cellular crescents, interstitial inflammation, tubular atrophy and interstitial fibrosis. ANCA-positive LN patients receiving mycophenolate mofetil as induction therapy had a higher remission rate and better renal outcomes than those receiving cyclophosphamide. During follow-up, end-stage renal disease developed in seven (14.29%) ANCA-positive LN patients, all of them were MPO-ANCA positive. Conclusions The characteristics of ANCA-positive LN were massive haematuria and advanced renal insufficiency. We observed a higher remission rate and better prognoses when using mycophenolate mofetil than when using cyclophosphamide as induction therapy.
What problem does this paper attempt to address?